Education & Practice Resources

Bookmark / Share
Email This

Errata - Therapeutic Choices

Sixth Edition, 2011

Correction in Chapter 3, Attention-Deficit Hyperactivity Disorder, p. 33

  • The first sentence of the fifth paragraph should read "Long-acting formulations of mixed salts amphetamine (Adderall XR), methylphenidate (Biphentin and Concerta) and lisdexamfetamine (Vyvanse) have a duration of action of 8-14 hours and are as effective as appropriately dosed shorter-acting stimulants."5, 9

Correction in Chapter 3, Attention-Deficit Hyperactivity Disorder, Table 2, p. 38

  • For dextroamphetamine immediate-release tablets, the Drug Interactions column should read: “Acidifying agents such as fruit juices or ascorbic acid can ↓ absorption and elimination of dextroamphetamine. Alkalinizing agents such as sodium bicarbonate can ↑ absorption and elimination of dextroamphetamine.”

Correction in Chapter 35, Hypertension, Table 6, p. 472

  • For trandolapril/verapamil, the paragraph on inotropic effects in the Drug Interactions column should read: “Additive negative inotropic effects with amiodarone, beta-blockers, digoxin.”

Correction in Chapter 60, Gastroesophageal Reflux Disease, p. 809

  • Under the heading, Choices during Pregnancy and Breastfeeding, the third sentence in the second paragraph should read: "If this fails, begin nonsystemic drug therapy with antacids, which generally provide immediate relief and are quite safe except for sodium bicarbonate, which can cause fluid retention and metabolic alkalosis."

Omission in Chapter 71, Menopause, p. 954.

Correction in Chapter 81, Osteoporosis, Table 2, p. 1081

  • The entry for etidronate/calcium under the Drug column should be accompanied by a kidney icon with footnote "c".

Correction in Chapter 105, Sinusitis, p. 1358

  • Under the heading, Management of Sinusitis in Pregnancy, the last sentence of the first paragraph should read “NSAIDs, such as ibuprofen, are an alternative but should be avoided in the third trimester because of the risk of premature closure of the ductus arteriosus.”

Correction in Chapter 107, Influenza, Figure 2, p. 1385

Correction in Chapter 108, Community-acquired Pneumonia, p. 1397

  • The first sentence of the second paragraph should read “The CURB-65 criteria predicts risk of death and assigns 1 point for each of the following: new onset confusion, urea >7 mmol/L, respiratory rate ≥30 breaths/min, systolic blood pressure <90 mm Hg or diastolic blood pressure ≤60 mm Hg and age ≥65 years.”

Correction in Chapter 117, Herpesvirus Infections, Table 1, p. 1567

  • The entry for valacyclovir under the Dose column should read "Treatment: 2 g BID po x 1 day
    Suppression: 500 mg po daily x 4 mo"

Correction in Chapter 120, Infections in the Cancer Patient, Figure 1, p. 1616

Fifth Edition, 2007

Correction in Chapter 1, Acute Agitation, Table 1, p. 9

  • The entry for carbamazepine under the Drug Interactions Column should read "Induces cytochrome P450 enzymes; increases clearance of many other drugs such as oral contraceptives, lovastatin, meperidine, morphine, nifedipine, oxycodone, trazodone."

Correction in Chapter 3, Attention-Deficit Hyperactivity Disorder, Table 2,  p. 37

  • For dextroamphetamine immediate-release tablets, the Drug Interactions column should read: “Acidifying agents such as fruit juices or ascorbic acid can ↓ absorption and elimination of dextroamphetamine. Alkalinizing agents such as sodium bicarbonate can ↑ absorption and elimination of dextroamphetamine.”

Corrections in Chapter 27, Diabetes Mellitus

Correction in Chapter 32, Hypertension, Table 5, p. 413

  • The entry for Diabetes mellitus without nephropathy under the Notes/Cautions column should read "Nephropathy is defined as an albumin to creatinine ratio (ACR) > 2 mg/mmol in men and > 2.8 mg/mmol in women."

Correction in Chapter 32, Hypertension, Table 6, p. 426

  • For trandolapril/verapamil, the paragraph on inotropic effects in the Drug Interactions column should read: “Additive negative inotropic effects with amiodarone, beta-blockers, digoxin.”

Correction in Chapter 33, Stable Angina, Table 2, p. 442

  • The entry for diltiazem under the dose column should read "Give CD and XC formulations once daily".

Correction in Chapter 39, Supraventricular Tachycardia

Corrections in Chapter 48, Asthma in Infants and Children

  • Table 1, p. 644. The entries for for fluticasone propionate DPI or pMDI plus spacer should read under the Moderate Dose column 201-500 mcg, and under the High Dose column greater than 500 mcg.
  • Table 2, p. 652. The entry for montelukast under the Comments column should read: "Levels may be decreased by carbamazepine, rifampin, phenytoin"

Correction in Chapter 49, Chronic Obstructive Pulmonary Disease, Table 4, p. 669

  • The entry for Theophylline Preparations under the Drug Interactions column should read: "Decreased theophylline serum levels: alcohol, carbamazepine, phenobarbital, phenytoin, rifampin and tobacco smoking" and "Increased theophylline serum levels: amiodarone, cimetidine, ciprofloxacin, clarithromycin, erythromycin, fluvoxamine, isoniazid, mexiletine, propranolol, verapamil"

Correction in Chapter 64, Menopause, p. 864

  • Under the Nonhormonal Therapies heading, the last sentence of the second paragraph should read: "Progesterone cream cannot be recommended because it does not prevent endometrial hyperplasia when used in combination with estrogen therapy in women with an intact uterus.6"

Correction in Chapter 93, Acute Otitis Media, Table 1, pages 1191-2

Under the column entitled First Choice:

  • for Age <2 y With No Risk Factors as well as for Age >2 y With No Risk Factors should read "Standard-dose amoxicillin (40 mg/kg/day) divided BID to TID"
  • for Age >2 y With Risk Factors should read "High-dose amoxicillin"

Under the column entitled Treatment Failure Noted on Day 10-28, a new footnote "a" has been added "Choose an agent not previously used for the same infection"

Footnote "b" (formerly footnote "a") now correctly addresses "High-dose amoxicillin/clavulanate"

Please replace Table 1 with the corrected version attached here.

Corrections in Chapter 98, Community-acquired Pneumonia

  • Figure 1, p. 1251. The statement "≥ 90 points and not hypoxemica" should read " 90 points and not hypoxemica". A corrected version is provided below. Please print and insert into your copy of Therapeutic Choices, 5th edition.
  • Table 4, p.1255. The entry for telithromycin under the Comments column should read: "Telithromycin increases levels of atorvastatin, lovastatin, simvastatin, digoxin, itraconazole, ketoconazole. Itraconazole, ketoconazole increase levels of telithromycin."

Correction in Chapter 99, Tuberculosis, Table 2, p.1272

  • Ethambutol dose under DOTS should read DOTS: 50 mg/kg 2x/wk (up to 4.0 g) or 25-30 mg/kg 3x/wk (up to 2.4 g).

Correction in Chapter 104, Sexually Transmitted Infections, Table 7, p. 1357

  • The entry for ciprofloxacin under the Comments column should read "decreased levels with concurrent use of antacids, iron or with didanosine (buffered formulations)."

Correction in Chapter 105, Herpesvirus Infections, Table 1, p. 1379

  • The entry for valacyclovir under the Dose column should read "Treatment: 2 g BID po x 1 day
    Suppression: 500 mg po daily x 4 mo"